MarketPulse

RSV vaccine

2 articles
BenzingaBenzinga··Vandana Singh

GSK Expands RSV Vaccine Access to Younger High-Risk Adults, Broadening Market Opportunity

GSK's Arexvy RSV vaccine gains FDA approval for younger high-risk adults aged 18-49, expanding market beyond 60+ population on strong Phase 3b data and £198M Q4 sales.
GSKFDA approvalRSV vaccine
The Motley FoolThe Motley Fool··Adria Cimino

Moderna Charts Post-Pandemic Course With Pipeline Diversification Strategy

Moderna shifts from pandemic revenues toward diversified pipeline including seasonal vaccines and oncology treatments, targeting cash breakeven by 2028 amid FDA progress on flu vaccine candidate.
MRNAFDA approvalmRNA technology